Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives
Authors:
Open Access
- 20 July 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1211426
Abstract
X-linked hypophosphatemia (XLH) is a rare, progressive, genetic disease with multisystem impact that typically begins to manifest in early childhood. Two treatment options exist: oral phosphate in combination with active vitamin D (“conventional therapy”) and a fully human monoclonal anti-FGF23 antibody, burosumab. The clinical benefit of conventional therapy in adults is limited, and poor tolerance and complications are common. Burosumab was first approved as a treatment for XLH in 2018 and its disease-modifying benefits in clinical trials in children suggest burosumab treatment could also alter the disease course in adults. Without long-term clinical data on multiple XLH-related sequelae available, the results of an elicitation exercise are reported, in which eight global experts in XLH posited how long-term treatment with burosumab is anticipated to impact the life course of clinical sequelae in adults with XLH. Based on their clinical experiences, the available evidence and their disease understanding, the experts agreed that some long-term benefits of using burosumab are likely in adults with XLH even if they have a misaligned skeleton from childhood. Burosumab treatment is anticipated to reduce the incidence of fractures and halt the progression of clinical sequelae associated with conventional therapy. While the trajectories for established dental abscesses are not expected to improve with burosumab treatment, dental abscess development may be prevented. Starting treatment with burosumab in childhood to increase the likelihood of an aligned skeleton and continuation into and throughout adulthood to maintain euphosphatemia may optimize patient outcomes, although future real-world investigation is required to support this hypothesis.Keywords
Funding Information
- Kyowa Kirin
This publication has 54 references indexed in Scilit:
- FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2–SGK1 signaling pathwayBone, 2012
- An Atypical Degenerative Osteoarthropathy in Hyp Mice is Characterized by a Loss in the Mineralized Zone of Articular CartilageCalcified Tissue International, 2011
- A clinician's guide to X-linked hypophosphatemiaJournal of Bone and Mineral Research, 2011
- Dentin structure in familial hypophosphatemic rickets: benefits of vitamin D and phosphate treatmentOral Diseases, 2007
- Hearing impairment in familial X-linked hypophosphatemic ricketsEuropean Journal of Pediatrics, 2004
- Early Treatment Improves Growth and Biochemical and Radiographic Outcome in X-Linked Hypophosphatemic RicketsThe Journal of Clinical Endocrinology & Metabolism, 2003
- Human Fibroblast Growth Factor-23 Mutants Suppress Na+-dependent Phosphate Co-transport Activity and 1α,25-Dihydroxyvitamin D3 ProductionJournal of Biological Chemistry, 2003
- A gene (PEX) with homologies to endopeptidases is mutated in patients with X–linked hypophosphatemic ricketsNature Genetics, 1995
- Effects of Therapy in X-Linked Hypophosphatemic RicketsNew England Journal of Medicine, 1991
- Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseasesPain, 1983